Incremental predictive value of liver fat fraction based on spectral detector CT for major adverse cardiovascular events in T2DM patients with suspected coronary artery disease

WHAT IS CURRENTLY KNOWN ABOUT THIS TOPIC?: T2DM is associated with increased MACE rates, underscoring the need for improved risk prediction. CACS is a well-established tool for MACE risk assessment but may not capture all risk factors. Hepatic steatosis is a common comorbidity in metabolic syndrome and T2DM. WHAT IS THE KEY RESEARCH QUESTION?: Does the incorporation of LFF derived from SDCT into existing risk prediction models enhance the accuracy of MACE forecasting in patients with T2DM? WHAT IS NEW?: SDCT-LFF measurement introduces a more accurate method for assessing hepatic steatosis. LFF as an independent predictor of MACE in T2DM patients is a novel finding. The study presents LFF as an additional tool for risk stratification, complementing FRS and CACS. HOW MIGHT THIS STUDY INFLUENCE CLINICAL PRACTICE?: Study findings may guide personalized prevention for T2DM patients at higher MACE risk.